Status:
TERMINATED
APERTO CVS PMCF Study
Lead Sponsor:
Cardionovum GmbH
Collaborating Sponsors:
CliPS Service
OPIS srl
Conditions:
Dialysis; Complications
Central Vein Obstruction
Eligibility:
All Genders
18+ years
Brief Summary
Prospective Observational Single Arm study aimed to assess safety and effectiveness of APERTO OTW DCB in treating stenosis and restenosis of central veins in dialysis patients
Detailed Description
The APERTO CVS PMCF study is aimed to evaluate safety and effectiveness of treatment of central veins (re)stenosis in dialysis patients at short and mid-term follow up, after treatment with APERTO OTW...
Eligibility Criteria
Inclusion
- Patients age \>18, no pregnant women, able to perform fup visits, life expectancy \> 12 months
- Dialysis patients undergoing endovascular angioplasty due to clinically symptomatic stenosis (de novo or restenosis) of the central veins with significant (\>50%) stenosis and diameter
- The target lesion consists of one or more lesions with a target lesion length of less than or equal to 100 mm
- The target blood vessel diameter of the target lesion is between 6.0 and 16.0 mm (in angiographic or ultrasound evaluation);
- If there are other non-target lesions, then non-target lesions must be successfully cured with a not drug coated balloon before treating the target lesion;
Exclusion
- Patients with CVS observed and estimated as nonsignificant (\< 50% stenosis) or a vessel \> 12 mm in diameter by visual estimation;
- the patient is now participating in another clinical trial to evaluate drug or medical device;
- patient enrolled for this trial before;
- prenatal pregnancy test result for women of childbearing potential is non-negative, Lactating woman;
- patients, who underwent major surgical procedures (such as thoracotomy, craniotomy, etc.) within 30 days prior to the study;
- patients scheduled to undergo major surgery (eg, thoracotomy, craniotomy, etc.) within 30 days after enrolment;
- central veins lesions have been already treated with DCB before
- presence of a bare metal stent (BMS) or stent graft or vascular access thrombosis in central veins
- patients allergic or intolerant to paclitaxel, or contrast media;
- patients whose life expectancy is less than 1 year
- presence of Thrombus in central veins
- tumor compression
- thoracic inlet syndrome
- patients implanted with pacing or cardioverter devices with leads
- any other central line within the target lesion
- Patients with any contraindications as mentioned in the Instructions for Use (IFU) of the Investigational Device
Key Trial Info
Start Date :
January 25 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2023
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT04514406
Start Date
January 25 2021
End Date
December 1 2023
Last Update
February 7 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Vivantes Klinikum
Berlin, Germany, 10249
2
St.Franziskus Hospital
Münster, Germany, 48145